Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33307 RadNet, Inc. (Exact name of registrant as specified in its charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or Delaware 13-3326724 (State or oth ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33307 RadNet, Inc. (Exact name of registrant as specified in its charter) Delaware 13-3326724 (State or other ju ...

Financial Data and Key Metrics Changes - For Q2 2023, the company reported revenue of $401.3 million and adjusted EBITDA of $63.7 million, excluding AI segment losses [7] - Net income for Q2 2023 was $8.4 million, compared to $7.9 million in Q2 2022, with diluted net income per share at $0.12 versus $0.13 in the prior year [12] - The company increased its 2023 revenue guidance by $25 million at the low end and $10 million at the high end, now projecting total net revenue between $1,575 million and $1,610 million [14] Business Line Data and Key Metrics Changes - The imaging center segment revenue increased by 13.8% year-over-year, with adjusted EBITDA rising by 14.7% [119] - AI revenue grew 109% year-over-year, primarily driven by the enhanced breast cancer detection program [4] - The company lowered its revenue guidance for the AI segment by $5 million, now estimating between $11 million and $13 million for the year [36] Market Data and Key Metrics Changes - The company noted a shift in patient volumes from expensive hospital-based imaging to more cost-effective outpatient settings, benefiting its business model [2] - Medicare reimbursement cuts are anticipated to impact revenue by approximately $7 million to $9 million in 2024, but the company expects to mitigate this through increases from commercial payers [18][51] Company Strategy and Development Direction - The company is focusing on expanding its digital health platform and AI initiatives to enhance operational efficiency and reduce reliance on labor [19][20] - Plans include opening 12 new centers, with five expected to be operational by year-end 2023, to address growing demand [71] - The company aims to leverage technology to improve patient experience and operational processes, particularly through generative AI [74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth through investments in technology and digital health initiatives, despite challenges in the labor market [44] - The company anticipates continued strong demand for imaging services, supported by advancements in technology and an aging population [116] - Management believes that the final Medicare reimbursement rules may be less severe than proposed, based on historical legislative actions [18] Other Important Information - The company reported a significant reduction in reliance on contract labor, now at about 50% of last year's levels, due to improved staffing [55] - The accounts receivable balance increased by $8.1 million from year-end 2022, reflecting higher procedural volumes [35] - The company has a cash balance of $357 million and is undrawn on its $195 million revolving line of credit [34] Q&A Session Summary Question: Sustainability of strong demand trends and organic growth rates - Management emphasized that investment in the digital health platform and generative AI will be key to sustaining growth and improving operational efficiency [44] Question: Update on contract labor costs and labor environment - Management confirmed that reliance on contract labor has decreased significantly, and they expect continued improvement in staffing levels [55] Question: Equity earnings of joint ventures and future expectations - Management indicated that one quarter's performance does not indicate a trend, and they expect the line item to stabilize [59] Question: Capacity for MRI and PET scans in light of increasing demand - Management noted that while demand is high, staffing remains a challenge, but they are implementing technology to improve capacity [94] Question: Capital allocation priorities post-equity raise - Management plans to invest in de novos, upgrade technology, and potentially pay down debt, depending on cash flow projections [99]

RadNet, Inc. (NASDAQ:RDNT) Q1 2023 Earnings Conference Call May 9, 2023 10:30 AM ET Company Participants Howard Berger - Chairman, President & CEO Mark Stolper - Executive VP & CFO Conference Call Participants Brian Tanquilut - Jefferies LLC John Ransom - Raymond James Lawrence Solow - CJS Securities Operator Good morning, and welcome to the RadNet, Inc. First Quarter 2023 Financial Results Call. All participants will be in a listen-only mode. [Operator Instructions] Please note this event is recorded. I ...

FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33307 RadNet, Inc. (Exact name of registrant as specified in its charter) Delaware 13-3326724 (State or other j ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33307 RadNet, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 1 ...

RadNet, Inc. (NASDAQ:RDNT) Q4 2022 Earnings Conference Call February 28, 2023 10:30 AM ET Company Participants Mark Stolper - EVP and CFO Howard Berger - CEO Conference Call Participants Brian Tanquilut - Jefferies John Ransom - Raymond James Mitra Ramgopal - Sidoti & Company Operator Greetings, and welcome to the RadNet Inc. Fourth Quarter 2022 Financial Results Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33307 RadNet, Inc. (Exact name of registrant as specified in its charter) Delaware 13-3326724 (State or oth ...

Financial Data and Key Metrics Changes - For Q3 2022, RadNet reported revenue of $349.1 million from its Imaging Centers segment, a 5.1% increase from the previous year, while adjusted EBITDA decreased by 8.5% to $50.2 million [29][30] - The overall revenue, including the AI segment, was $350 million, reflecting a 5.2% increase from $332.7 million in Q3 2021 [30] - Net income for Q3 2022 was $668,000, down from $16.2 million in Q3 2021, with diluted net income per share decreasing from $0.30 to $0.01 [31] Business Line Data and Key Metrics Changes - Revenue from Imaging Centers increased by 5.2%, with aggregate procedural volume up by 5.7% and same-store procedure volumes rising by 3.9% [8] - MRI volume increased by 10.8%, CT volume by 9.6%, and PET/CT volume by 11.5% compared to the previous year [35] - Total procedures performed in Q3 2022 reached 2,311,448, with routine imaging exams accounting for 75.4% of the volume [36] Market Data and Key Metrics Changes - The demand for imaging services is strong, with increasing patient volumes across all regional markets, particularly noted in October as the strongest revenue month of the year [12] - Staffing shortages have impacted the ability to meet demand, but recent improvements in filling open positions have been observed [11] Company Strategy and Development Direction - The company is developing 15 new facilities, with three already open and eight expected to generate revenue by the end of Q2 2023 [14] - Expansion through joint ventures with hospitals and health systems is a key strategy, with 33% of facilities now in partnerships [15] - The acquisition of Heart&Lung Health, a teleradiology network, is part of a strategy to enhance cancer screening services [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for Q4 2022 and 2023, citing strong demand and improved staffing conditions [12][62] - The company anticipates that higher labor costs will persist but is implementing measures to manage these costs effectively [63][68] - The healthcare sector is expected to remain resilient during potential recessionary conditions, with a continued shift towards outpatient services [75] Other Important Information - Cash balance at the end of Q3 was over $95 million, with a record low DSO of 37 days [24][40] - Revised financial guidance for 2022 includes unchanged revenue expectations and adjusted EBITDA guidance of $203 million to $208 million [42] Q&A Session Summary Question: Thoughts on Q3 results and cost challenges - Management acknowledged labor challenges impacting both revenue and costs, but noted improvements in staffing and confidence moving into Q4 [57][60] Question: Outlook for 2023 and EBITDA growth - Management highlighted initiatives to expand hospital partnerships and new centers, projecting significant revenue growth from these efforts [65][66] Question: Details on the Enhanced Breast Cancer Detection program - The pilot program in Delaware has received positive feedback, with a significant percentage of patients enrolling [69][70] Question: Impact of potential Alzheimer's drugs on imaging - Management is already conducting studies related to Alzheimer's and expects increased demand for imaging services if new drugs are approved [71][72] Question: Resilience of the business in a recession - Management believes healthcare is generally insulated from recessionary impacts and expects continued volume growth due to demographic trends [75][78] Question: Expansion in Arizona and growth opportunities - Management confirmed confidence in the Arizona market and plans for further expansion in collaboration with Dignity Health [79][80] Question: Prioritization of growth opportunities - All growth avenues, including JVs, M&A, and AI investments, are considered priorities, with a focus on teleradiology as a future growth area [81][83]

RadNet, Inc. (NASDAQ:RDNT) Q2 2022 Earnings Conference Call August 9, 2022 10:30 AM ET Company Participants Mark Stolper - EVP and CFO Howard Berger - CEO Conference Call Participants Brian Tanquilut - Jefferies Sarah James - Barclays Mitra Ramgopal - Sidoti Operator Good day, ladies and gentlemen, and welcome to the RadNet, Inc. Second Quarter 2022 Financial Results Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr. Mark Stolper, Executive V ...